J Frontier (2934) · RiskRestated
Risk of Non-Compliance with Pharmaceutical Regulations
First written in FY2021. 1 of 2 entries say "Restated". Latest entry: FY2026.
2entries
6years
0from disclosures
How it moved
Same theme, other companies
Regulatory and licensing continuity risk in the pharmaceutical and long-term care businessesA theme 25 companies write about · 25 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2021: 2 of 14 companies on the "Worse" side.
16 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 25 companies compared. The sentences above are computed from all 25.Full recordFilings, disclosures and news, newest first
- FY2026RestatedAnnual report
「万が一、当社グループの事業活動が本法に抵触した場合は、業務の停止や許可の取消し等の処分を受ける可能性があり」
医薬品販売・広告における薬機法抵触リスクを、許可取消し等の影響とともに継続開示している。 - FY2021First statedAnnual report
「If our business activities were to violate this Act, we could be subject to measures such as suspension of operations or revocation of permits.」
The Company discloses the possibility that violations of the Pharmaceuticals and Medical Devices Act in pharmaceutical sales or advertising could lead to suspension of operations or revocation of permits.